Bremelanotide (PT-141)
PT-141 / Vyleesi
- Peptide length
- 7 amino acids
Cyclic peptide
Open the sources to check how the studies were done and what they can support.
A cyclic melanocortin agonist used in the FDA-approved medicine Vyleesi for a specifically defined hypoactive sexual desire disorder population.
- Family
- Melanocortin agonist
- Research target
- Melanocortin receptors
- Molecular form
- Cyclic peptide
What to know about the research
The approved indication is narrower than general libido or sexual-performance claims. Study population, route and cardiovascular precautions matter.
Check the exact compound
Bremelanotide and melanotan II are distinct cyclic molecules. Describing PT-141 as simply a linearized melanotan II is incorrect.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries